Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 75 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Neurocrine Biosciences Clear all
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD

NCT05165394
View directory record Official record
Conditions
Anhedonia, Major Depressive Disorder
Interventions
Placebo, NBI-1065846
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
22
States / cities
Birmingham, Alabama • Garden Grove, California • Lemon Grove, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 17, 2026, 4:32 AM EDT
Completed Phase 2 Interventional Results available

NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder

NCT01393600
View directory record Official record
Conditions
Tardive Dyskinesia
Interventions
NBI-98854, Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
11
States / cities
Little Rock, Arkansas • National City, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Oct 17, 2026, 4:32 AM EDT
Completed Phase 2 Interventional Results available

Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome

NCT03444038
View directory record Official record
Conditions
Tourette Syndrome
Interventions
Valbenazine
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
6 Years to 18 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
36
States / cities
Sun City, Arizona • Anaheim, California • San Diego, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Oct 17, 2026, 4:32 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate 3 Dose Levels of Luvadaxistat of Adults With Negative Symptoms of Schizophrenia

NCT03382639
View directory record Official record
Conditions
Schizophrenia
Interventions
Luvadaxistat, Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 60 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
16
States / cities
Garden Grove, California • Lemon Grove, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 17, 2026, 4:32 AM EDT
Completed Phase 1 Interventional

Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease

NCT03065192
View directory record Official record
Conditions
Idiopathic Parkinson's Disease, Parkinson's Disease, Basal Ganglia Disease, Brain Diseases, Central Nervous System Diseases, Movement Disorders, Nervous System Diseases, Neurodegenerative Diseases, Parkinsonian Disorders
Interventions
VY-AADC01
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
40 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
4
States / cities
San Francisco, California • Atlanta, Georgia • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Oct 17, 2026, 4:32 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia

NCT02274558
View directory record Official record
Conditions
Tardive Dyskinesia
Interventions
NBI-98854, Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
48
States / cities
Little Rock, Arkansas • Anaheim, California • Glendale, California + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 17, 2026, 4:32 AM EDT
Recruiting Phase 2 Interventional

An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania

NCT07288320
View directory record Official record
Conditions
Bipolar I Disorder, Mania
Interventions
NBI-1117568, Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
11
States / cities
Little Rock, Arkansas • Cerritos, California • Garden Grove, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 17, 2026, 4:32 AM EDT
Recruiting Phase 3 Interventional

NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

NCT06963021
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
NBI-1065845, Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
15
States / cities
Chino, California • Los Angeles, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 17, 2026, 4:32 AM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Development of Healthcare Transition for Patients With Congenital Adrenal Hyperplasia

NCT07611786
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia
Interventions
exposure to healthcare transition protocol
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
16 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 17, 2026, 4:32 AM EDT
Completed Phase 2 Interventional

NBI-3001 Followed by Surgery in Treating Patients With Recurrent Glioblastoma Multiforme

NCT00014677
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
interleukin-4 PE38KDEL cytotoxin, conventional surgery
Biological · Procedure
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
4
States / cities
La Jolla, California • Atlanta, Georgia • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Oct 17, 2026, 4:32 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder

NCT06267846
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
NBI-1070770, Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
13
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Lemon Grove, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 17, 2026, 4:32 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome

NCT02679079
View directory record Official record
Conditions
Tourette Syndrome
Interventions
NBI-98854, Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
6 Years to 17 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
44
States / cities
Sun City, Arizona • Springdale, Arkansas • Long Beach, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2021 · Synced Oct 17, 2026, 4:32 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia

NCT04490915
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia
Interventions
Crinecerfont, Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
20
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 17, 2026, 4:32 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome

NCT03325010
View directory record Official record
Conditions
Tourette Syndrome
Interventions
Valbenazine, Placebo oral capsule
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
6 Years to 17 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
34
States / cities
Sun City, Arizona • Rogers, Arkansas • Anaheim, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Oct 17, 2026, 4:32 AM EDT
Completed Phase 4 Interventional Results available

The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine

NCT03698331
View directory record Official record
Conditions
Tardive Dyskinesia (TD)
Interventions
Valbenazine, Placebo oral capsule
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
16
States / cities
Anaheim, California • Glendale, California • Norwalk, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Oct 17, 2026, 4:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild,Moderate, or Severe Hepatic Insufficiency

NCT01916993
View directory record Official record
Conditions
Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects
Interventions
NBI-98854 50 mg capsule
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
3
States / cities
Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 16, 2014 · Synced Oct 17, 2026, 4:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 Tablet Formulation

NCT03101293
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-831
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 17, 2026, 4:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Relative Bioavailability (BA) and Effect of Food on TAK-831 Tablet Formulations in Healthy Participants

NCT03706469
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-831 T2, TAK-831 T3
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
19 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 17, 2026, 4:32 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)

NCT04806451
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia
Interventions
Crinecerfont, Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
2 Years to 17 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Oct 17, 2026, 4:32 AM EDT
Recruiting Phase 3 Interventional

NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

NCT07114874
View directory record Official record
Conditions
Schizophrenia
Interventions
NBI-1117568
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
50
States / cities
Bryant, Arkansas • Little Rock, Arkansas • Cerritos, California + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 17, 2026, 4:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-label Study of the Effects of Elagolix in Adult Premenopausal Females

NCT01403038
View directory record Official record
Conditions
Folliculogenesis
Interventions
elagolix
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
20
States / cities
Colorado Springs, Colorado • Denver, Colorado • Lonetree, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2013 · Synced Oct 17, 2026, 4:32 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Adults With Congenital Adrenal Hyperplasia

NCT03525886
View directory record Official record
Conditions
CAH - Congenital Adrenal Hyperplasia
Interventions
NBI-74788
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Aurora, Colorado • Indianapolis, Indiana • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Oct 17, 2026, 4:32 AM EDT
Terminated Phase 3 Interventional

Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia

NCT05654870
View directory record Official record
Conditions
Schizophrenia
Interventions
Valbenazine, Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
13 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
3
States / cities
San Jose, California • Coral Gables, Florida • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Oct 17, 2026, 4:32 AM EDT
Not listed No phase listed Observational

Real-World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents

NCT03062033
View directory record Official record
Conditions
Tardive Dyskinesia
Interventions
Not listed
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
34
States / cities
Little Rock, Arkansas • Anaheim, California • Long Beach, California + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2017 · Synced Oct 17, 2026, 4:32 AM EDT